Skip to main content

Table 1 Demographic characteristics and co-morbidities for the 84 virologically suppressed, HIV-infected patients entered in this study

From: Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

  All NVP-XR NVP-IR P
N = 84 N = 35 N = 49
Age, mean years (± SD) 41 (13) 43 (12) 40 (14) 0.38
Gender, Male (%) 72 (85.7) 30 (85.7) 42 (85.7) 1.0
Body weight, kg (± SD) 66.3 (12.3) 67.1 (13.1) 65.7 (11.8) 0.62
Risk factor
 MSM, n (%) 64 (82.1) 29 (82.8) 35 (71.4) 0.22
 Heterosexual, n (%) 10 (11.9) 3 (8.6) 7 (14.3) 0.51
 IVDU, n (%) 9 (10.7) 3 (8.6) 6 (12.2) 0.73
 Vertical transmission, n (%) 1 (1.1) 0 (0) 1 (2.0) 1.0
Underlying disease
 Diabetes mellitus, n (%) 3 (3.6) 0 (0.0) 3 (6.1) 0.26
 CKD, n (%) 0 (0.0) 0 (0.0) 0 (0.0)  
 Autoimmune disease, n (%) 0 (0.0) 0 (0.0) 0 (0.0)  
 Chronic hepatitis B infection, n (%) 8 (9.5) 4 (11.4) 4 (8.2) 0.71
 Chronic hepatitis C infection, n (%) 6 (7.1) 1 (2.9) 5 (10.2) 0.39
Backbone of cART     <0.001
 Kivexa, n (%) 43 (51.2) 27 (77.1) 16 (32.7) <0.001
 Combivir, n (%) 27 (32.1) 0 (0.0) 27 (55.1) <0.001
 TDF+ 3TC, n (%) 8 (9.5) 4 (11.4) 4 (8.1) 0.71
 DDI + 3TC, n (%) 5 (6.0) 4 (11.4) 1 (2.0) 0.16
 Kaletra, n (%) 1 (1.2) 0 (0.0) 1 (2.0) 1.0
Third drug of cARTa
 NVP-IR 200 mg twice daily, n (%) 60 (71.4) 11 (31.4) 49 (100) <0.001
 NVP-IR 400 mg once daily, n (%) 24 (28.6%) 24 (68.6) 0 (0.0) <0.001
Duration of continued virological suppression at entering this study, mean days (±SD) 993 (758) 1042 (565) 959 (875) 0.60
History of virological blip before entering this study, n (%) 10 (11.9) 3 (8.6) 7 (14.3) 0.51
Baseline CD4, mean cells/mm3 (±SD) 489 (244) 463 (193) 508 (276) 0.41
Patient follow-up, days (±SD) 552 (170) 555 (172) 549 (170) 0.86
  1. MSM men who have sex with men, CKD chronic kidney disease, DDI didanosine, IVDU intravenous drug user, NVP nevirapine, SD standard deviation, TDF tenofovir, 3TC lamivudine
  2. aIn the NVP-XR group, this means the nNRTIs prescribed prior to switching to NVP-XR-containing HAART